{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:55:42Z","timestamp":1792788942457,"version":"4.5.0"},"reference-count":84,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,5,3]],"date-time":"2018-05-03T00:00:00Z","timestamp":1525305600000},"content-version":"vor","delay-in-days":367,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Finnish Academy Center of Excellence in Cardiovascular and Metabolic Diseases"},{"name":"British Heart Foundation Chair of Translational Cardiovascular Sciences","id":[{"id":"https:\/\/ror.org\/02wdwnk04","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/100010663","name":"ERC","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010663","id-type":"DOI","asserted-by":"publisher"}]},{"name":"VASCMIR"},{"name":"CleverGenes"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.ymthe.2017.03.027","type":"journal-article","created":{"date-parts":[[2017,4,4]],"date-time":"2017-04-04T20:34:16Z","timestamp":1491338056000},"page":"1095-1106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":164,"title":["Cardiovascular Gene Therapy: Past, Present, and Future"],"prefix":"10.1016","volume":"25","author":[{"given":"Seppo","family":"Yl\u00e4-Herttuala","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew H.","family":"Baker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2017.03.027_bib1","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1126\/science.2119055","article-title":"Site-specific gene expression in\u00a0vivo by direct gene transfer into the arterial wall","volume":"249","author":"Nabel","year":"1990","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2017.03.027_bib2","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1038\/nm1195-1148","article-title":"A pilot study of ex\u00a0vivo gene therapy for homozygous familial hypercholesterolaemia","volume":"1","author":"Grossman","year":"1995","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2017.03.027_bib3","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/S0140-6736(96)03361-2","article-title":"Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb","volume":"348","author":"Isner","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2017.03.027_bib4","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1089\/hum.1998.9.10-1481","article-title":"Adenovirus-mediated gene transfer to lower limb artery of patients with chronic critical leg ischemia","volume":"9","author":"Laitinen","year":"1998","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2017.03.027_bib5","doi-asserted-by":"crossref","first-page":"1651","DOI":"10.1093\/eurheartj\/ehw019","article-title":"Gene therapy for the treatment of heart failure: promise postponed","volume":"37","author":"Hulot","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ymthe.2017.03.027_bib6","first-page":"10","article-title":"Angiogenic gene therapy in cardiovascular diseases: dream or vision?","volume":"2017","author":"Yl\u00e4-Herttuala","year":"2017","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ymthe.2017.03.027_bib7","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1038\/mt.2012.194","article-title":"Endgame: glybera finally recommended for approval as the first gene therapy drug in the European union","volume":"20","author":"Yl\u00e4-Herttuala","year":"2012","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.03.027_bib8","doi-asserted-by":"crossref","unstructured":"Hartikainen, J., Hassinen, I., Hedman, A., Kivel\u00e4, A., Saraste, A., Knuuti, J., Husso, M., Mussalo, H., Hedman, M., Rissanen, T.T., et\u00a0al. (2017) Adenoviral intramyocardial VEGF-D\u0394N\u0394C gene transfer increases myocardial perfusion reserve in refractory angina patients. A phase I\/IIa study with one year follow-up. Submitted.","DOI":"10.1093\/eurheartj\/ehx352"},{"key":"10.1016\/j.ymthe.2017.03.027_bib9","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1089\/hum.2016.131","article-title":"Intramyocardial gene therapy directed to hibernating heart muscle using a combination of electromechanical mapping and positron emission tomography","volume":"27","author":"Hassinen","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2017.03.027_bib10","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1038\/nm0603-694","article-title":"Gene transfer as a tool to induce therapeutic vascular growth","volume":"9","author":"Yl\u00e4-Herttuala","year":"2003","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2017.03.027_bib11","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/nrcardio.2013.200","article-title":"Treatment of refractory angina in patients not suitable for revascularization","volume":"11","author":"Henry","year":"2014","journal-title":"Nat. Rev. Cardiol."},{"key":"10.1016\/j.ymthe.2017.03.027_bib12","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1161\/CIRCRESAHA.116.304346","article-title":"Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data","volume":"116","author":"Gy\u00f6ngy\u00f6si","year":"2015","journal-title":"Circ. Res."},{"key":"10.1016\/j.ymthe.2017.03.027_bib13","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1186\/s13287-015-0143-9","article-title":"Endpoints in stem cell trials in ischemic heart failure","volume":"6","author":"Banovic","year":"2015","journal-title":"Stem Cell Res. Ther."},{"key":"10.1016\/j.ymthe.2017.03.027_bib14","doi-asserted-by":"crossref","first-page":"982","DOI":"10.1016\/j.jacc.2004.12.068","article-title":"Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial","volume":"45","author":"Kastrup","year":"2005","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.ymthe.2017.03.027_bib15","doi-asserted-by":"crossref","first-page":"2677","DOI":"10.1161\/01.CIR.0000070540.80780.92","volume":"107","author":"Hedman","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2017.03.027_bib16","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1038\/sj.gt.3302802","article-title":"Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF(121) (AdVEGF121) versus maximum medical treatment","volume":"13","author":"Stewart","year":"2006","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2017.03.027_bib17","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1038\/mt.2009.70","article-title":"VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial","volume":"17","author":"Stewart","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.03.027_bib18","doi-asserted-by":"crossref","first-page":"813","DOI":"10.4244\/EIJV6I7A140","article-title":"A randomised, double-blind, placebo-controlled, multicentre study of the safety and efficacy of BIOBYPASS (AdGVVEGF121.10NH) gene therapy in patients with refractory advanced coronary artery disease: the NOVA trial","volume":"6","author":"Kastrup","year":"2011","journal-title":"EuroIntervention"},{"key":"10.1016\/j.ymthe.2017.03.027_bib19","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1093\/eurheartj\/ehl117","article-title":"Intramyocardial injection of vascular endothelial growth factor-A165 plasmid followed by granulocyte-colony stimulating factor to induce angiogenesis in patients with severe chronic ischaemic heart disease","volume":"27","author":"Ripa","year":"2006","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ymthe.2017.03.027_bib20","unstructured":"Corautus Genetics (2006). Corautus announces termination of patient enrollment in GENASIS severe angina clinical trial. http:\/\/www.corautus.com."},{"key":"10.1016\/j.ymthe.2017.03.027_bib21","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1161\/01.CIR.100.5.468","article-title":"Angiogenesis gene therapy: phase I assessment of direct intramyocardial administration of an adenovirus vector expressing VEGF121 cDNA to individuals with clinically significant severe coronary artery disease","volume":"100","author":"Rosengart","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2017.03.027_bib22","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1253\/circj.CJ-09-0594","article-title":"Myocardial transfection of hypoxia inducible factor-1alpha via an adenoviral vector during coronary artery bypass grafting. - A multicenter phase I and safety study -","volume":"74","author":"Kilian","year":"2010","journal-title":"Circ. J."},{"key":"10.1016\/j.ymthe.2017.03.027_bib23","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1038\/gt.2009.4","article-title":"Eight-year safety follow-up of coronary artery disease patients after local intracoronary VEGF gene transfer","volume":"16","author":"Hedman","year":"2009","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2017.03.027_bib24","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1089\/hum.2012.137","article-title":"Long-term follow-up assessment of a phase 1 trial of angiogenic gene therapy using direct intramyocardial administration of an adenoviral vector expressing the VEGF121 cDNA for the treatment of diffuse coronary artery disease","volume":"24","author":"Rosengart","year":"2013","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2017.03.027_bib25","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1038\/gt.2011.109","article-title":"10-year safety follow-up in patients with local VEGF gene transfer to ischemic lower limb","volume":"19","author":"Muona","year":"2012","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2017.03.027_bib26","doi-asserted-by":"crossref","first-page":"2172","DOI":"10.1038\/sj.mt.6300302","article-title":"Umbilical cord blood-derived progenitor cells enhance muscle regeneration in mouse hindlimb ischemia model","volume":"15","author":"Koponen","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.03.027_bib27","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1089\/humc.2013.054","article-title":"Safety of direct cardiac administration of AdVEGF-All6A+, a replication-deficient adenovirus vector cDNA\/genomic hybrid expressing all three major isoforms of human vascular endothelial growth factor, to the ischemic myocardium of rats","volume":"24","author":"Kaminsky","year":"2013","journal-title":"Hum. Gene Ther. Clin. Dev."},{"key":"10.1016\/j.ymthe.2017.03.027_bib28","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1016\/j.jacc.2007.06.010","article-title":"Effects of Ad5FGF-4 in patients with angina: an analysis of pooled data from the AGENT-3 and AGENT-4 trials","volume":"50","author":"Henry","year":"2007","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.ymthe.2017.03.027_bib29","doi-asserted-by":"crossref","first-page":"1749","DOI":"10.1517\/14712598.2013.827656","article-title":"Evaluation of ASPIRE trial: a Phase III pivotal registration trial, using intracoronary administration of Generx (Ad5FGF4) to treat patients with recurrent angina pectoris","volume":"13","author":"Kaski","year":"2013","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ymthe.2017.03.027_bib30","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1007\/s11033-008-9315-3","article-title":"Phase I clinical trial on intracoronary administration of Ad-hHGF treating severe coronary artery disease","volume":"36","author":"Yang","year":"2009","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.ymthe.2017.03.027_bib31","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/gt.2012.87","article-title":"Intramyocardial transfer of hepatocyte growth factor as an adjunct to CABG: phase I clinical study","volume":"20","author":"Kim","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2017.03.027_bib32","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1161\/CIRCRESAHA.109.200774","article-title":"Efficient regulation of VEGF expression by promoter-targeted lentiviral shRNAs based on epigenetic mechanism: a novel example of epigenetherapy","volume":"105","author":"Turunen","year":"2009","journal-title":"Circ. Res."},{"key":"10.1016\/j.ymthe.2017.03.027_bib33","doi-asserted-by":"crossref","first-page":"6848271","DOI":"10.1155\/2017\/6848271","article-title":"Thymosin \u03b24 Improves Differentiation and Vascularization of EHTs","volume":"2017","author":"Ziegler","year":"2017","journal-title":"Stem Cells Int."},{"key":"10.1016\/j.ymthe.2017.03.027_bib34","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1111\/j.1749-6632.2012.06693.x","article-title":"Molecular and cellular mechanisms of thymosin \u03b24-mediated cardioprotection","volume":"1269","author":"Hinkel","year":"2012","journal-title":"Ann. N Y Acad. Sci."},{"key":"10.1016\/j.ymthe.2017.03.027_bib35","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1038\/nature10188","article-title":"De novo cardiomyocytes from within the activated adult heart after injury","volume":"474","author":"Smart","year":"2011","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2017.03.027_bib36","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1161\/CIRCULATIONAHA.115.020143","article-title":"Selective Stimulation of Cardiac Lymphangiogenesis Reduces Myocardial Edema and Fibrosis Leading to Improved Cardiac Function Following Myocardial Infarction","volume":"133","author":"Henri","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2017.03.027_bib37","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/j.ymthe.2016.12.022","article-title":"Human Pericardial Fluid Contains Exosomes Enriched with Cardiovascular-Expressed MicroRNAs and Promotes Therapeutic Angiogenesis","volume":"25","author":"Beltrami","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.03.027_bib38","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ymthe.2016.09.001","article-title":"Macrophage-Derived mir-155-Containing Exosomes Suppress Fibroblast Proliferation and Promote Fibroblast Inflammation during Cardiac Injury","volume":"25","author":"Wang","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.03.027_bib39","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1024\/0301-1526\/a000298","article-title":"Gene therapy for therapeutic angiogenesis in peripheral arterial disease - a systematic review and meta-analysis of randomized, controlled trials","volume":"42","author":"Hammer","year":"2013","journal-title":"Vasa"},{"key":"10.1016\/j.ymthe.2017.03.027_bib40","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1006\/mthe.2002.0638","article-title":"Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study","volume":"6","author":"M\u00e4kinen","year":"2002","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.03.027_bib41","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1089\/hum.2006.17.683","article-title":"Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial","volume":"17","author":"Kusumanto","year":"2006","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2017.03.027_bib42","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/01.CIR.0000093398.16124.29","volume":"108","author":"Rajagopalan","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2017.03.027_bib43","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1177\/1074248415574336","article-title":"pCMV-vegf165 Intramuscular Gene Transfer is an Effective Method of Treatment for Patients With Chronic Lower Limb Ischemia","volume":"20","author":"Deev","year":"2015","journal-title":"J.\u00a0Cardiovasc. Pharmacol. Ther."},{"key":"10.1016\/j.ymthe.2017.03.027_bib44","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/mt.2008.33","article-title":"Therapeutic angiogenesis with intramuscular NV1FGF improves amputation-free survival in patients with critical limb ischemia","volume":"16","author":"Nikol","year":"2008","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.03.027_bib45","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(11)60394-2","article-title":"Effect of fibroblast growth factor NV1FGF on amputation and death: a randomised placebo-controlled trial of gene therapy in critical limb ischaemia","volume":"377","author":"Belch","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2017.03.027_bib46","series-title":"Sendai Virus Vector","first-page":"183","article-title":"Gene Therapy for peripheral arterial disease using Sendai Virus vector: from preclinical studies to the Phase I\/IIa clinical trial","author":"Yonemitsu","year":"2013"},{"key":"10.1016\/j.ymthe.2017.03.027_bib47","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.ahj.2007.01.038","article-title":"Results from a phase II multicenter, double-blind placebo-controlled study of Del-1 (VLTS-589) for intermittent claudication in subjects with peripheral arterial disease","volume":"153","author":"Grossman","year":"2007","journal-title":"Am. Heart J."},{"key":"10.1016\/j.ymthe.2017.03.027_bib48","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1161\/CIRCULATIONAHA.110.009407","article-title":"Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication","volume":"124","author":"Creager","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2017.03.027_bib49","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.jacc.2006.09.053","article-title":"Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine","volume":"49","author":"Yl\u00e4-Herttuala","year":"2007","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.ymthe.2017.03.027_bib50","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1242\/dmm.010413","article-title":"Promoting blood vessel growth in ischemic diseases: challenges in translating preclinical potential into clinical success","volume":"6","author":"Dragneva","year":"2013","journal-title":"Dis. Model. Mech."},{"key":"10.1016\/j.ymthe.2017.03.027_bib51","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1016\/j.ymthe.2016.12.019","article-title":"Phase Ib Safety, Two-Dose Study of MultiGeneAngio in Patients with Chronic Critical Limb Ischemia","volume":"25","author":"Flugelman","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.03.027_bib52","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1111\/j.1365-2362.2009.02208.x","article-title":"Antegrade flow and peripheral resistance determine the level of endogenous arteriogenesis in patients with superficial femoral artery occlusion","volume":"39","author":"Vajanto","year":"2009","journal-title":"Eur. J. Clin. Invest."},{"key":"10.1016\/j.ymthe.2017.03.027_bib53","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1161\/CIRCULATIONAHA.107.727347","article-title":"Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia","volume":"118","author":"Powell","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2017.03.027_bib54","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1038\/gt.2010.51","article-title":"Randomized, double-blind, placebo-controlled clinical trial of hepatocyte growth factor plasmid for critical limb ischemia","volume":"17","author":"Shigematsu","year":"2010","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2017.03.027_bib55","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1517\/14712598.2014.872237","article-title":"Current gene therapy trials for vascular diseases","volume":"14","author":"Halonen","year":"2014","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ymthe.2017.03.027_bib56","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0140-6736(16)00082-9","article-title":"Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): a randomised, multinational, double-blind, placebo-controlled, phase 2b trial","volume":"387","author":"Greenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2017.03.027_bib57","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1038\/mt.2015.158","article-title":"Gene Therapy for Heart Failure: Back to the Bench","volume":"23","author":"Yl\u00e4-Herttuala","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.03.027_bib58","doi-asserted-by":"crossref","first-page":"2228","DOI":"10.1093\/eurheartj\/ehv254","article-title":"Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial","volume":"36","author":"Chung","year":"2015","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ymthe.2017.03.027_bib59","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1161\/CIRCRESAHA.108.178459","article-title":"Overexpression of vascular endothelial growth factor-B in mouse heart alters cardiac lipid metabolism and induces myocardial hypertrophy","volume":"103","author":"Karpanen","year":"2008","journal-title":"Circ. Res."},{"key":"10.1016\/j.ymthe.2017.03.027_bib60","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1161\/CIRCULATIONAHA.108.816454","article-title":"Vascular endothelial growth factor-B induces myocardium-specific angiogenesis and arteriogenesis via vascular endothelial growth factor receptor-1- and neuropilin receptor-1-dependent mechanisms","volume":"119","author":"L\u00e4hteenvuo","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2017.03.027_bib61","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nature08945","article-title":"Vascular endothelial growth factor B controls endothelial fatty acid uptake","volume":"464","author":"Hagberg","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2017.03.027_bib62","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.jacc.2015.04.071","article-title":"Intracoronary Cytoprotective Gene Therapy: A Study of VEGF-B167 in a Pre-Clinical Animal Model of Dilated Cardiomyopathy","volume":"66","author":"Woitek","year":"2015","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.ymthe.2017.03.027_bib63","doi-asserted-by":"crossref","first-page":"92ra64","DOI":"10.1126\/scitranslmed.3002097","article-title":"Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model","volume":"3","author":"Pleger","year":"2011","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2017.03.027_bib64","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1038\/mt.2014.127","article-title":"Cardiac I-1c overexpression with reengineered AAV improves cardiac function in swine ischemic heart failure","volume":"22","author":"Ishikawa","year":"2014","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.03.027_bib65","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1210\/jc.2011-3002","article-title":"Effect of alipogene tiparvovec (AAV1-LPL(S447X)) on postprandial chylomicron metabolism in lipoprotein lipase-deficient patients","volume":"97","author":"Carpentier","year":"2012","journal-title":"J.\u00a0Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ymthe.2017.03.027_bib66","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1089\/hum.2015.158","article-title":"Long-Term Retrospective Analysis of Gene Therapy with Alipogene Tiparvovec and Its Effect on Lipoprotein Lipase Deficiency-Induced Pancreatitis","volume":"27","author":"Gaudet","year":"2016","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.ymthe.2017.03.027_bib67","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1016\/S0140-6736(16)31009-1","article-title":"Antisense oligonucleotides targeting apolipoprotein(a) in people with raised lipoprotein(a): two randomised, double-blind, placebo-controlled, dose-ranging trials","volume":"388","author":"Viney","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2017.03.027_bib68","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1056\/NEJMoa1609243","article-title":"A Highly Durable RNAi Therapeutic Inhibitor of PCSK9","volume":"376","author":"Fitzgerald","year":"2017","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2017.03.027_bib69","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1056\/NEJMoa1400283","article-title":"Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia","volume":"373","author":"Gaudet","year":"2015","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2017.03.027_bib70","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1016\/j.jacc.2013.07.081","article-title":"Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial","volume":"62","author":"Thomas","year":"2013","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.ymthe.2017.03.027_bib71","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1161\/ATVBAHA.116.308258","article-title":"Local Vascular Gene Therapy With Apolipoprotein A-I to Promote Regression of Atherosclerosis","volume":"37","author":"Wacker","year":"2017","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ymthe.2017.03.027_bib72","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1172\/JCI114271","article-title":"Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man","volume":"84","author":"Yl\u00e4-Herttuala","year":"1989","journal-title":"J.\u00a0Clin. Invest."},{"key":"10.1016\/j.ymthe.2017.03.027_bib73","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/cvr\/cvq235","article-title":"Silencing of either SR-A or CD36 reduces atherosclerosis in hyperlipidaemic mice and reveals reciprocal upregulation of these receptors","volume":"88","author":"M\u00e4kinen","year":"2010","journal-title":"Cardiovasc. Res."},{"key":"10.1016\/j.ymthe.2017.03.027_bib74","doi-asserted-by":"crossref","first-page":"1715","DOI":"10.1016\/j.jacc.2011.07.017","article-title":"Human oxidation-specific antibodies reduce foam cell formation and atherosclerosis progression","volume":"58","author":"Tsimikas","year":"2011","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.ymthe.2017.03.027_bib75","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1161\/01.RES.82.3.306","article-title":"Gene therapy for restenosis: are we ready?","volume":"82","author":"DeYoung","year":"1998","journal-title":"Circ. Res."},{"key":"10.1016\/j.ymthe.2017.03.027_bib76","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S0735-1097(01)01741-7","volume":"39","author":"Kutryk","year":"2002","journal-title":"J.\u00a0Am. Coll. Cardiol."},{"key":"10.1016\/j.ymthe.2017.03.027_bib77","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1089\/hum.2006.17.405","article-title":"Extracellular superoxide dismutase with vaccinia virus\u00a0anti-inflammatory protein 35K or tissue inhibitor of metalloproteinase-1: Combination gene therapy in the treatment of vein graft stenosis in rabbits","volume":"17","author":"Turunen","year":"2006","journal-title":"Hum. Gene Ther."},{"issue":"11, Suppl","key":"10.1016\/j.ymthe.2017.03.027_bib78","doi-asserted-by":"crossref","first-page":"S135","DOI":"10.1161\/CIRCULATIONAHA.110.012732","article-title":"Sustained reduction of vein graft neointima formation by ex\u00a0vivo TIMP-3 gene therapy","volume":"124","author":"George","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.ymthe.2017.03.027_bib79","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.jvs.2005.12.058","article-title":"Results of PREVENT III: a multicenter, randomized trial of edifoligide for the prevention of vein graft failure in lower extremity bypass surgery","volume":"43","author":"Conte","year":"2006","journal-title":"J.\u00a0Vasc. Surg."},{"key":"10.1016\/j.ymthe.2017.03.027_bib80","doi-asserted-by":"crossref","first-page":"2446","DOI":"10.1001\/jama.294.19.2446","article-title":"Efficacy and safety of edifoligide, an E2F transcription factor decoy, for prevention of vein graft failure following coronary artery bypass graft surgery: PREVENT IV: a randomized controlled trial","volume":"294","author":"Alexander","year":"2005","journal-title":"JAMA"},{"key":"10.1016\/j.ymthe.2017.03.027_bib81","unstructured":"Ark Therapeutics. (2009) Ark Therapeutics completes potency test qualification enabling Trinam Phase III trial to begin. Quick Facts RTTNews. 8.1.2009."},{"key":"10.1016\/j.ymthe.2017.03.027_bib82","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/sj.mt.6300175","article-title":"Current status of cardiovascular gene therapy","volume":"15","author":"Rissanen","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2017.03.027_bib83","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1038\/gt.2011.66","article-title":"Long-term VEGF-A expression promotes aberrant angiogenesis and fibrosis in skeletal muscle","volume":"18","author":"Karvinen","year":"2011","journal-title":"Gene Ther."},{"key":"10.1016\/j.ymthe.2017.03.027_bib84","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1093\/eurheartj\/ehq433","article-title":"Capillary enlargement, not sprouting angiogenesis, determines beneficial therapeutic effects and side effects of angiogenic gene therapy","volume":"32","author":"Korpisalo","year":"2011","journal-title":"Eur. Heart J."}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001617301272?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001617301272?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,9,20]],"date-time":"2019-09-20T12:17:18Z","timestamp":1568981838000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001617301272"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":84,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2017,5]]}},"alternative-id":["S1525001617301272"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2017.03.027","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiovascular Gene Therapy: Past, Present, and Future","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2017.03.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 The American Society of Gene and Cell Therapy.","name":"copyright","label":"Copyright"}]}}